TRIPS Agreement

In The You On AI Field Guide

The historical record on American IP practice during the country's industrialization is starkly at odds with the requirements TRIPS imposes globally. American copyright law explicitly excluded foreign authors until 1891, allowing American publishers to reprint British books without compensation throughout the formative period of American publishing. American patent law was substantially weaker than European patent law throughout the nineteenth century, and American firms routinely copied European technology with neither legal nor cultural opprobrium. The Singer sewing machine, the steamboat, the telegraph, the railroad — all involved substantial American copying of European originals.

The contrast with TRIPS requirements is sharp. American developmental practice required exactly the IP flexibility that TRIPS now prohibits for developing nations. The flexibility was used successfully to build American industrial capability. The same flexibility, sought by contemporary developing nations attempting to build pharmaceutical, software, or AI capability, is denied through the binding international commitments that TRIPS established.

The most visible damage from TRIPS has been in pharmaceutical access. The agreement's requirements for patent protection on medicines have produced documented increases in drug prices in developing countries, with measurable consequences for public health outcomes. The 2001 Doha Declaration on TRIPS and Public Health partially mitigated these effects by affirming flexibility for compulsory licensing in public health emergencies, but the underlying constraint remains.

The relevance to AI is direct. TRIPS-style IP protections constrain the development of alternatives to incumbent AI platforms, restrict the ability to reverse-engineer or modify proprietary models, and limit the ability of developing nations to build domestic AI capability through learning from incumbents — exactly the strategy that successful developers historically used. The IP regime that was justified as encouraging innovation has, in practice, served to lock in incumbent advantages and constrain the development paths available to followers.

Origin

TRIPS emerged from a sustained advocacy campaign by major American intellectual-property-intensive industries during the 1980s. The Intellectual Property Committee, founded in 1986 by twelve major American corporations, drove the campaign to embed IP requirements in the trade agreements that became the WTO framework. The strategy was to use trade access as leverage for IP commitments that could not be obtained through standalone IP negotiations.

The agreement was concluded as part of the Uruguay Round in 1994 and entered into force with the WTO in 1995. Developing countries were given transition periods of varying lengths to bring their IP regimes into compliance, but the substantive requirements were uniform. Subsequent amendments — particularly the 2001 Doha Declaration and the 2003 Decision on Implementation of Paragraph 6 — have created limited flexibility for public health purposes, but the core regime remains in place.

Key Ideas

Asymmetric historical practice. The IP regime imposed globally is substantially stricter than the regime the wealthy nations operated under during their own development.

Trade leverage. The use of trade access as leverage for IP commitments — embedding IP requirements in trade agreements rather than negotiating standalone IP treaties.

Pharmaceutical impact. Documented increases in drug prices and constraints on access to essential medicines in developing countries.

AI implications. Constraints on the development of alternatives to incumbent AI platforms and on the technology learning strategies that successful developers historically used.